Industry News
Pharmaceutical Industry News
GSK and Shionogi’s ViiV…
GSK and Shionogi’s ViiV Healthcare is seeking to raise awareness around what the company sees as a forgotten element in HIV: young people with the infection.
As geopolitics bring reshoring…
As geopolitics bring reshoring interest to a fever pitch, the United States Pharmacopeia (USP) is adding to the impetus for local drug production with a warning that homes in on the pharmaceutical building blocks known
Novartis is making further…
Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to remove 114 positions as the drugmaker rejigs its sales team for rare disease medicines.
Charles River Laboratories has…
Charles River Laboratories has backed an American Heart Association campaign, joining forces with the nonprofit on cardiovascular disease awareness, prevention and community health initiatives.
Envision Pharma Group has hired…
Envision Pharma Group has hired clinical research veteran Nick Jones as president of its Envision Medical Communications (EMC) business.
The wait is over. Fierce Biotech…
The wait is over. Fierce Biotech has unveiled its ranking of the top 10 pharma R&D budgets of 2025. In this episode of "The Top Line," Darren Incorvaia and Eric Sagonowsky break down the biggest
La pastilla contra la calvicie que está redefiniendo la masculinidad
La finasterida, un fármaco para frenar la caída del cabello, está cambiando la forma en que los hombres envejecen y cómo se perciben a sí mismos.
Portuguese biopharma Bial is…
Portuguese biopharma Bial is launching a year-long disease awareness campaign that’s intended to boost understanding of Parkinson’s disease and its often subtle and early-stage symptoms.
Novartis is launching a…
Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the goal of roughly tripling their footprint by 2030.
Too much information, uncertainty…
Too much information, uncertainty and financial worries are hitting Americans when it comes to making important choices for their health.
Amneal and BioCorRx have earned…
Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by accusations of violating the agency’s drug marketing rules.
Takeda ended its neurogenerative…
Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei scrapped a minimum purchase requirement in their vaccine distribution agreement. Shionogi secured funding from the U.S. government to boost the domestic
Vanda is kicking off a phase 3…
Vanda is kicking off a phase 3 trial which will evaluate the efficacy and safety of its newly approved motion sickness drug Nereus in patients receiving a high dose of a GLP-1 agonist. The primary endpoint
Omnichannel isn’t a content…
Omnichannel isn’t a content problem. It’s an access problem. See how compliant AI connects HCPs and patients to the right answers instantly.
Specialty assets company Garda…
Specialty assets company Garda Therapeutics has acquired Assertio and its chemotherapy supportive care treatment Rolvedon for $125.1 million. In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics
AbbVie is spearheading a new…
AbbVie is spearheading a new battle in pharma's long-running fight to reform the federal government’s 340B drug discount program.
Robert F. Kennedy Jr. is starting…
Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he
How a New York Times Reporter Covers the Illegal Drug Trade
A new series on dangerous synthetic drugs called for sources on the other side of the law.
A federal judge rejected the Trump…
A federal judge rejected the Trump administration's bid to dismiss a group of states' lawsuit challenging Robert F. Kennedy Jr.'s restructuring of the Department of Health and Human Services.
From a negative phase 3 readout…
From a negative phase 3 readout and a seemingly tightening regulatory climate to a grueling three-month review extension, Travere has defied the odds, securing Filspari a landmark FDA approval as the first treatment for the